Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders

Journal of Aging Research

Volumn 2012, Issue , 2012, Pages

  Qian, Hao ^a   Luo, Na ^a   Chi, Yuling ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BERAPROST; CAMONAGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DAZOXIBEN; ICOSANOID; ILOPROST; NAFTIDROFURYL OXALATE; PICOTAMIDE; PROCYCLIN; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN H2; TERUTROBAN; THROMBOXANE; THROMBOXANE A2; TREPROSTINIL; UNCLASSIFIED DRUG; VIPROSTOL;

AGING; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ENZYME INHIBITION; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; MOLECULAR MECHANICS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION; THROMBOSIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

EID: 84868271246     PISSN: 20902204     EISSN: 20902212     Source Type: Journal    
DOI: 10.1155/2012/121390     Document Type: Review

References (253)

1. Docherty J. R., Cardiovascular responses in ageing: a review. Pharmacological Reviews 1990 42 2 103 125 2-s2.0-0025330663 (Pubitemid 20217962)
2. Zeiher A. M., Drexler H., Saurbier B., Just H., Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. Journal of Clinical Investigation 1993 92 2 652 662 2-s2.0-0027249912 (Pubitemid 23262382)
3. Brandes R. P., Fleming I., Busse R., Endothelial aging. Cardiovascular Research 2005 66 2 286 294 2-s2.0-16344372461 10.1016/j.cardiores.2004.12.027 (Pubitemid 40471043)
4. Lakatta E. G., Levy D., Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation 2003 107 1 139 146 2-s2.0-0037422592 10.1161/01.CIR.0000048892.83521.58 (Pubitemid 36070946)
5. Rothwell P. M., Coull A. J., Silver L. E., Fairhead J. F., Giles M. F., Lovelock C. E., Redgrave J. N. E., Bull L. M., Welch S. J. V., Cuthbertson F. C., Binney L. E., Gutnikov S. A., Anslow P., Banning A. P., Mant D., Mehta Z., Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005 366 9499 1773 1783 2-s2.0-27844562639 10.1016/S0140-6736(05) 67702-1 (Pubitemid 41642641)
6. Jayakody L., Kappagoda T., Senaratne M. P., Thomson A. B., Impairment of endothelium-dependent relaxation: an early marker for atherosclerosis in the rabbit. British Journal of Pharmacology 1988 94 2 335 346 2-s2.0-0023737410
7. Elliott H. L., Endothelial dysfunction in cardiovascular disease: risk factor, risk marker, or surrogate end point? Journal of Cardiovascular Pharmacology 1998 32 supplement 3 S74 S77 2-s2.0-0032442919 (Pubitemid 29019757)
8. Fathi R., Haluska B., Isbel N., Short L., Marwick T. H., The relative importance of vascular structure and function in predicting cardiovascular events. Journal of the American College of Cardiology 2004 43 4 616 623 2-s2.0-1242317678 10.1016/j.jacc.2003.09.042 (Pubitemid 38229534)
9. Mancini G. B., Vascular structure versus function: is endothelial dysfunction of independent prognostic importance or not? Journal of the American College of Cardiology 2004 43 4 624 628 2-s2.0-1242272744 10.1016/j.jacc.2003. 11.017 (Pubitemid 38229535)
10. Herrera M. D., Mingorance C., Rodríguez-Rodríguez R., Alvarez de Sotomayor M., Endothelial dysfunction and aging: an update. Ageing Research Reviews 2010 9 2 142 152 2-s2.0-77949266553 10.1016/j.arr.2009.07.002
11. Furchgott R. F., Zawadzki J. V., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980 288 5789 373 376 2-s2.0-0019195506 (Pubitemid 11169009)
12. Davignon J., Ganz P., Role of endothelial dysfunction in atherosclerosis. Circulation 2004 109 23 III27 III32 2-s2.0-2942733214 (Pubitemid 38786440)
13. Celermajer D. S., Sorensen K. E., Spiegelhalter D. J., Georgakopoulos D., Robinson J., Deanfield J. E., Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. Journal of the American College of Cardiology 1994 24 2 471 476 2-s2.0-0027990857 (Pubitemid 24246550)
14. Taddei S., Virdis A., Mattei P., Ghiadoni L., Gennari A., Fasolo C. B., Sudano I., Salvetti A., Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995 91 7 1981 1987 2-s2.0-0028907886
15. Taddei S., Virdis A., Mattei P., Ghiadoni L., Fasolo C. B., Sudano I., Salvetti A., Hypertension causes premature aging of endothelial function in humans. Hypertension 1997 29 3 736 743 2-s2.0-0031020629 (Pubitemid 27097978)
16. Egashira K., Inou T., Hirooka Y., Kai H., Sugimachi M., Suzuki S., Kuga T., Urabe Y., Takeshita A., Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation 1993 88 1 77 81 2-s2.0-0027252930 (Pubitemid 23195435)
17. Küng C. F., Lüscher T. F., Different mechanisms of endothelial dysfunction with aging and hypertension in rat aorta. Hypertension 1995 25 2 194 200 2-s2.0-0028833338
18. Gerhard M., Roddy M. A., Creager S. J., Creager M. A., Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans. Hypertension 1996 27 4 849 853 2-s2.0-0030006173 (Pubitemid 26113830)
19. Eskurza I., Monahan K. D., Robinson J. A., Seals D. R., Effect of acute and chronic ascorbic acid on flow-mediated dilatation with sedentary and physically active human ageing. Journal of Physiology 2004 556 1 315 324 2-s2.0-1942438660 10.1113/jphysiol.2003.057042 (Pubitemid 38519054)
20. Rodríguez-Mañas L., Vallejo S., López-Dóriga P., Solís J., Petidier R., Montes M., Nevado J., Castro M., Gómez-Guerrero C., Peiró C., Sánchez-Ferrer C. F., Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation. Aging Cell 2009 8 3 226 238 2-s2.0-66249112184 10.1111/j.1474-9726.2009.00466.x
21. Shimizu I., Toda N., Alterations with age of the response to vasodilator agents in isolated mesenteric arteries of the beagle. British Journal of Pharmacology 1986 89 4 769 778 2-s2.0-0022993654 (Pubitemid 17200583)
22. Moritoki H., Hosoki E., Ishida Y., Age-related decrease in endothelium-dependent dilator response to histamine in rat mesenteric artery. European Journal of Pharmacology 1986 126 1-2 61 67 2-s2.0-0022920830 (Pubitemid 16014732)
23. Hongo K., Nakagomi T., Kassell N. F., Sasaki T., Lehman M., Vollmer D. G., Tsukahara T., Ogawa H., Torner J., Effects of aging and hypertension on endothelium-dependent vascular relaxation in rat carotid artery. Stroke 1988 19 7 892 897 2-s2.0-0023780531
24. Hynes M. R., Duckles S. P., Effect of increasing age on the endothelium-mediated relaxation of rat blood vessels in vitro. Journal of Pharmacology and Experimental Therapeutics 1987 241 2 387 392 2-s2.0-0023201980 (Pubitemid 17111536)
25. Koga T., Takata Y., Kobayashi K., Takishita S., Yamashita Y., Fujishima M., Age and hypertension promote endothelium-dependent contractions to acetylcholine in the aorta of the rat. Hypertension 1989 14 5 542 548 2-s2.0-0024426160 (Pubitemid 19270520)
26. Atkinson J., Tatchum-Talom R., Capdeville-Atkinson C., Reduction of endothelial function with age in the mesenteric arterial bed of the normotensive rat. British Journal of Pharmacology 1994 111 4 1184 1188 2-s2.0-0028280956 (Pubitemid 24148789)
27. Tominaga M., Fujii K., Abe I., Takata Y., Kobayashi K., Fujishima M., Hypertension and ageing impair acetylcholine-induced vasodilation in rats. Journal of Hypertension 1994 12 3 259 268 2-s2.0-0028288139 (Pubitemid 24090030)
28. Stewart K. G., Zhang Y., Davidge S. T., Aging increases PGHS-2-dependent vasoconstriction in rat mesenteric arteries. Hypertension 2000 35 6 1242 1247 2-s2.0-0034048530 (Pubitemid 30413658)
29. Abeywardena M. Y., Jablonskis L. T., Head R. J., Age- and hypertension-induced changes in abnormal contractions in rat aorta. Journal of Cardiovascular Pharmacology 2002 40 6 930 937 2-s2.0-0036890888 10.1097/00005344-200212000-00015 (Pubitemid 35365092)
30. Muller-Delp J. M., Spier S. A., Ramsey M. W., Delp M. D., Aging impairs endothelium-dependent vasodilation in rat skeletal muscle arterioles. American Journal of Physiology 2002 283 4 H1662 H1672 2-s2.0-0036784007
31. Gomez E., Schwendemann C., Roger S., Simonet S., Paysant J., Courchay C., Verbeuren T. J., Félétou M., Aging and prostacyclin responses in aorta and platelets from WKY and SHR rats. American Journal of Physiology 2008 295 5 H2198 H2211 2-s2.0-57049092313 10.1152/ajpheart.00507.2008
32. Gendron M. È., Thorin-Trescases N., Villeneuve L., Thorin E., Aging associated with mild dyslipidemia reveals that COX-2 preserves dilation despite endothelial dysfunction. American Journal of Physiology 2007 292 1 H451 H458 2-s2.0-33846233914 10.1152/ajpheart.00551.2006 (Pubitemid 46105209)
33. 2 production precede endothelial dysfunction in mice. American Journal of Physiology 2007 293 4 H2508 H2515 2-s2.0-35348967835 10.1152/ajpheart.00352.2007 (Pubitemid 47605897)
34. Haudenschild C. C., Prescott M. F., Chobanian A. V., Aortic endothelial and subendothelial cells in experimental hypertension and aging. Hypertension 1981 3 3 148 153 2-s2.0-0019826525 (Pubitemid 11013815)
35. Haudenschild C. C., Chobanian A. V., Blood pressure lowering diminishes age-related changes in the rat aortic intima. Hypertension 1984 6 2 I-62 I-68 2-s2.0-0021273537 (Pubitemid 14113583)
36. Soltis E. E., Effect of age on blood pressure and membrane-dependent vascular responses in the rat. Circulation Research 1987 61 6 889 897 2-s2.0-0023513867 (Pubitemid 18004585)
37. Koga T., Takata Y., Kobayashi K., Takishita S., Yamashita Y., Fujishima M., Ageing suppresses endothelium-dependent relaxation and generates contraction mediated by the muscarinic receptors in vascular smooth muscle of normotensive Wistar-Kyoto and spontaneously hypertensive rats. Journal of Hypertension 1988 6 4 S243 S245 2-s2.0-0024212486 (Pubitemid 19067449)
38. Iwama Y., Kato T., Muramatsu M., Asano H., Shimizu K., Toki Y., Miyazaki Y., Okumura K., Hashimoto H., Ito T., Satake T., Correlation with blood pressure of the acetylcholine-induced endothelium- derived contracting factor in the rat aorta. Hypertension 1992 19 4 326 332 2-s2.0-0026652816
39. Ferrari A. U., Radaelli A., Centola M., Aging and the cardiovascular system. Journal of Applied Physiology 2003 95 6 2591 2597 2-s2.0-3042691909 (Pubitemid 37445007)
40. Matz R. L., Andriantsitohaina R., Age-related endothelial dysfunction: potential implications for pharmacotherapy. Drugs and Aging 2003 20 7 527 550 2-s2.0-0038171187 10.2165/00002512-200320070-00005 (Pubitemid 36688138)
41. Matz R. L., de Sotomayor M. A., Schott C., Stoclet J. C., Andriantsitohaina R., Vascular bed heterogeneity in age-related endothelial dysfunction with respect to NO and eicosanoids. British Journal of Pharmacology 2000 131 2 303 311 2-s2.0-0033778214
42. Barton M., Cosentino F., Brandes R. P., Moreau P., Shaw S., Lüscher T. F., Anatomic heterogeneity of vascular aging: role of nitric oxide and endothelin. Hypertension 1997 30 4 817 824 2-s2.0-0030774840 (Pubitemid 27441107)
43. Fleming I., Busse R., NO: the primary EDRF. Journal of Molecular and Cellular Cardiology 1999 31 1 5 14 2-s2.0-0033062909 10.1006/jmcc.1998.0839 (Pubitemid 29078214)
44. Tschudi M. R., Barton M., Bersinger N. A., Moreau P., Cosentino F., Noll G., Malinski T., Lüscher T. F., Effect of age on kinetics of nitric oxide release in rat aorta and pulmonary artery. Journal of Clinical Investigation 1996 98 4 899 905 2-s2.0-0029810053 (Pubitemid 26293306)
45. Smith W. L., Wmlis A. L., Localization of enzymes responsible for prostaglandin formation. Handbook of Eicosanoids: Prostaglandins and Related Lipids 1987 IA Boca Raton, Fla, USA CRC Press 175 184
46. Weeks J. R., Prostaglandins. Annual Review of Pharmacology 1972 12 317 336 2-s2.0-0015267690
47. Clyman R. I., Mauray F., Roman C., Rudolph A. M., PGE2 is a more potent vasodilator of the lamb ductus arteriosus than is either PGI2 or 6 keto PGF(1 α). Prostaglandins 1978 16 2 259 264 2-s2.0-0018199512 (Pubitemid 9026987)
48. 2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacology and Therapeutics 2008 118 1 18 35 2-s2.0-42649113385 10.1016/j.pharmthera.2008.01.001
49. Moncada S., Gryglewski R., Bunting S., Vane J. R., An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976 263 5579 663 665 2-s2.0-0017094798
50. Moncada S., Herman A. G., Higgs E. A., Vane J. R., Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thrombosis Research 1977 11 3 323 344 2-s2.0-0017749182 (Pubitemid 8197170)
51. Williams S. P., Dorn G. W. 2nd, Rapoport R. M., Prostaglandin I2 mediates contraction and relaxation of vascular smooth muscle. American Journal of Physiology 1994 267 2 H796 H803 2-s2.0-0027991908
52. Rapoport R. M., Williams S. P., Role of prostaglandins in acetylcholine-induced contraction of aorta from spontaneously hypertensive and Wistar-Kyoto rats. Hypertension 1996 28 1 64 75 2-s2.0-0029947695 (Pubitemid 26231092)
53. Gluais P., Lonchampt M., Morrow J. D., Vanhoutte P. M., Feletou M., Acetylcholine-induced endothelium-dependent contractions in the SHR aorta: the Janus face of prostacyclin. British Journal of Pharmacology 2005 146 6 834 845 2-s2.0-27744564624 10.1038/sj.bjp.0706390 (Pubitemid 41622250)
54. Bunting S., Gryglewski S., Moncada S., Vane J. R., Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 1976 12 6 897 913 2-s2.0-0017041860 (Pubitemid 8015243)
55. 2 and prostacyclin. Advances in Cyclic Nucleotide Research 1978 9 597 609 2-s2.0-0017872324
56. Moncada S., Vane J. R., The role of prostacyclin in vascular tissue. Desty's Federal Procedure 1979 38 1 66 71 2-s2.0-0018743451 (Pubitemid 9084965)
57. Shimokawa H., Flavahan N. A., Lorenz R. R., Vanhoutte P. M., Prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig. British Journal of Pharmacology 1988 95 4 1197 1203 2-s2.0-0024209706 (Pubitemid 19001162)
58. Abran D., Varma D. R., Chemtob S., Regulation of prostanoid vasomotor effects and receptors in choroidal vessels of newborn pigs. American Journal of Physiology 1997 272 3 R995 R1001 2-s2.0-0031004324
59. Katusic Z. S., Shepherd J. T., Vanhoutte P. M., Endothelium-dependent contractions to calcium ionophore A23187, arachidonic acid and acetylcholine in canine basilar arteries. Stroke 1988 19 4 476 479 2-s2.0-0023937250
60. 2 (TXA2) like substance. Life Sciences 1988 42 4 437 445 2-s2.0-0023854943 (Pubitemid 18064253)
61. Taddei S., Vanhoutte P. M., Role of endothelium in endothelin-evoked contractions in the rat aorta. Hypertension 1993 21 1 9 15 2-s2.0-0027393348 (Pubitemid 23006446)
62. 2 in the SHR aorta. Circulation Research 1995 76 6 1003 1010 2-s2.0-0029079634
63. 2 as endothelium-derived contracting factors. American Journal of Physiology 2006 291 5 H2255 H2264 2-s2.0-33751170898 10.1152/ajpheart.01115.2005
64. Gluais P., Vanhoutte P. M., Félétou M., Mechanisms underlying ATP-induced endothelium-dependent contractions in the SHR aorta. European Journal of Pharmacology 2007 556 13 107 114 2-s2.0-33846067638 10.1016/j.ejphar.2006.10.050 (Pubitemid 46073998)
65. Hirao A., Kondo K., Inui N., Umemura K., Ohashi K., Watanabe H., Cyclooxygenase-dependent vasoconstricting factor(s) in remodelled rat femoral arteries. Cardiovascular Research 2008 79 1 161 168 2-s2.0-45849137405 10.1093/cvr/cvn111 (Pubitemid 351881948)
66. 2 α in dogs. European Journal of Pharmacology 1973 24 1 61 66 2-s2.0-0015844048
67. Dusting G. J., Vane J. R., Some cardiovascular properties of prostacyclin (PGI2) which are not shared by PGE2. Circulation Research 1980 46 6 I183 I187 2-s2.0-0019137102 (Pubitemid 11205565)
68. Carter J., Reynoldson J. A., Thorburn G. D., The effects of certain vasodilating prostaglandins on the coronary and hindlimb vascular beds of the conscious sheep. Comparative Biochemistry and Physiology 1986 83 2 401 406 2-s2.0-0022596875 (Pubitemid 16119487)
69. 2 induces vasodilation and pruritus, but no protein extravasation in atopic dermatitis and controls. Journal of the American Academy of Dermatology 2002 47 1 28 32 2-s2.0-0036628537 10.1067/mjd.2002.120462
70. Gray S. J., Heptinstall S., The effects of PGE2 and CL 115,347, an antihypertensive PGE2 analogue, on human blood platelet behaviour and vascular contractility. European Journal of Pharmacology 1985 114 2 129 137 2-s2.0-0022269251 (Pubitemid 16255549)
71. Förstermann U., Mügge A., Alheid U., Bode S. M., Frölich J. C., Endothelium-derived relaxing factor (EDRF): a defence mechanism against platelet aggregation and vasospasm in human coronary arteries. European Heart Journal 1989 10 supplement F 36 43 2-s2.0-0024784438 (Pubitemid 20045695)
72. Fabre J. E., Nguyen M., Athirakul K., Coggins K., McNeish J. D., Austin S., Parise L. K., FitzGerald G. A., Coffman T. M., Koller B. H., Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. Journal of Clinical Investigation 2001 107 5 603 610 2-s2.0-0035098077 (Pubitemid 32205181)
73. Smith W. L., Prostaglandin biosynthesis and its compartmentation in vascular smooth muscle and endothelial cells. Annual Review of Physiology 1986 48 251 262 2-s2.0-0022559202 (Pubitemid 16047613)
74. Norel X., Prostanoid receptors in the human vascular wall. The Scientific World Journal 2007 7 1359 1374 2-s2.0-34548722249 10.1100/tsw.2007.184 (Pubitemid 47435435)
75. Singh N., Prasad S., Singer D. R., MacAllister R. J., Ageing is associated with impairment of nitric oxide and prostanoid dilator pathways in the human forearm. Clinical Science 2002 102 5 595 600 2-s2.0-0036257720 10.1042/CS20010262 (Pubitemid 34494202)
76. Wang M., Zukas A. M., Hui Y., Ricciotti E., Puré E., FitzGerald G. A., Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proceedings of the National Academy of Sciences of the United States of America 2006 103 39 14507 14512 2-s2.0-33749263692 10.1073/pnas.0606586103 (Pubitemid 44484780)
77. DeWitt D. L., Day J. S., Sonneburg W. K., Smith W. L., Concentrations of prostaglandin endoperoxide synthase and prostaglandin I2 synthase in the endothelium and smooth muscle of bovine aorta. Journal of Clinical Investigation 1983 72 6 1882 1888 2-s2.0-0021084823 (Pubitemid 14224392)
78. Doroudi R., Gan L. M., Selin Sjögren L., Jern S., Effects of shear stress on eicosanoid gene expression and metabolite production in vascular endothelium as studied in a novel biomechanical perfusion model. Biochemical and Biophysical Research Communications 2000 269 1 257 264 2-s2.0-0034607125 10.1006/bbrc.2000.2279 (Pubitemid 30440287)
79. Funk C. D., FitzGerald G. A., COX-2 inhibitors and cardiovascular risk. Journal of Cardiovascular Pharmacology 2007 50 5 470 479 2-s2.0-36348932768 10.1097/FJC.0b013e318157f72d (Pubitemid 350146448)
80. Topper J. N., Cai J., Falb D., Gimbrone M. A. Jr., Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proceedings of the National Academy of Sciences of the United States of America 1996 93 19 10417 10422 2-s2.0-0029790770
81. Onodera M., Morita I., Mano Y., Murota S., Differential effects of nitric oxide on the activity of prostaglandin endoperoxide H synthase-1 and -2 in vascular endothelial cells. Prostaglandins Leukotrienes and Essential Fatty Acids 2000 62 3 161 167 2-s2.0-0034068926 10.1054/plef.2000.0136 (Pubitemid 30333204)
82. Kawka D. W., Ouellet M., Hétu P. O., Singer I. I., Riendeau D., Double-label expression studies of prostacyclin synthase, thromboxane synthase and COX isoforms in normal aortic endothelium. Biochimica et Biophysica Acta 2007 1771 1 45 54 2-s2.0-33846094465 10.1016/j.bbalip.2006.09.015 (Pubitemid 46073877)
83. Tang E. H., Vanhoutte P. M., Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. Physiological Genomics 2008 32 3 409 418 2-s2.0-40149085142 10.1152/physiolgenomics.00136.2007 (Pubitemid 351328564)
84. Numaguchi Y., Harada M., Osanai H., Hayashi K., Toki Y., Okumura K., Ito T., Hayakawa T., Altered gene expression of prostacyclin synthase and prostacyclin receptor in the thoracic aorta of spontaneously hypertensive rats. Cardiovascular Research 1999 41 3 682 688 2-s2.0-0033040983 10.1016/S0008- 6363(98)00239-9 (Pubitemid 29130632)
85. Kang K. B., Rajanayagam M. A., van der Zypp A., Majewski H., A role for cyclooxygenase in aging-related changes of β -adrenoceptor- mediated relaxation in rat aortas. Naunyn-Schmiedeberg's Archives of Pharmacology 2007 375 4 273 281 2-s2.0-34247867979 10.1007/s00210-007-0153-y (Pubitemid 46701626)
86. Graham D. A., Rush J. W., Cyclooxygenase and thromboxane/prostaglandin receptor contribute to aortic endothelium-dependent dysfunction in aging female spontaneously hypertensive rats. Journal of Applied Physiology 2009 107 4 1059 1067 2-s2.0-70350129736 10.1152/japplphysiol.90785.2008
87. Wong W. T., Tian X. Y., Leung F. P., Liu L., Lee H. K., Ng C. F., Xu A., Yao X., Vanhoutte P. M., Tipoe G. L., Huang Y., Bone morphogenic protein-4 impairs endothelial function through oxidative stress-dependent cyclooxygenase-2 upregulation: implications on hypertension. Circulation Research 2010 107 8 984 991 2-s2.0-77958496539 10.1161/CIRCRESAHA.110.222794
88. Qu C., Leung S. W., Vanhoutte P. M., Man R. Y., Chronic inhibition of nitric-oxide synthase potentiates endothelium-dependent contractions in the rat aorta by augmenting the expression of cyclooxygenase-2. Journal of Pharmacology and Experimental Therapeutics 2010 334 2 373 380 2-s2.0-77954921263 10.1124/jpet.110.167098
89. 2 may be the endothelium-derived contracting factor released by acetylcholine in the aorta of the rat. Hypertension 1990 15 5 475 481 2-s2.0-0025195377 (Pubitemid 20148037)
90. Pagano P. J., Lin L., Sessa W. C., Nasjletti A., Arachidonic acid elicits endothelium-dependent release from the rabbit aorta of a constrictor prostanoid resembling prostaglandin endoperoxides. Circulation Research 1991 69 2 396 405 2-s2.0-0025770687
91. 2 are contractile factors in intrarenal arteries of spontaneously hypertensive rats. Hypertension 1992 19 6 795 798 2-s2.0-0026870921
92. 2 as an endothelium-derived contracting factor in diabetic state. Diabetes 1993 42 9 1246 1252 2-s2.0-0027337873 (Pubitemid 23259843)
93. 2 receptors on human endothelial cells. Circulation Research 1993 72 5 958 965 2-s2.0-0027339829 (Pubitemid 23105501)
94. 2 as an endothelium-derived contracting factor modulates endothelin-1-induced contraction. Journal of Hypertension 1994 12 4 383 390 2-s2.0-0028181814
95. 2-mediated mechanism of vascular contraction in hypertensive rats: relation to lipoxygenase and prostacyclin synthase activities. Circulation Research 1994 74 2 197 205 2-s2.0-0028179292
96. Félétou M., Verbeuren T. J., Vanhoutte P. M., Endothelium-dependent contractions in SHR: a tale of prostanoid TP and IP receptors. British Journal of Pharmacology 2009 156 4 563 574 2-s2.0-65349116560 10.1111/j.1476-5381.2008.00060.x
97. Hamberg M., Samuelsson B., Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proceedings of the National Academy of Sciences of the United States of America 1974 71 9 3400 3404 2-s2.0-0000822547
98. Hamberg M., Svensson J., Wakabayashi T., Samuelsson B., Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proceedings of the National Academy of Sciences of the United States of America 1974 71 2 345 349 2-s2.0-0346992906
99. Moncada S., Needleman P., Bunting S., Vane J. R., Prostaglandin endoperoxide and thromboxane generating systems and their selective inhibition. Prostaglandins 1976 12 3 323 335 2-s2.0-0017084547
100. 2 from prostaglandin endoperoxides. Nature 1976 261 5561 558 560 2-s2.0-0017309767 10.1038/261558a0
101. Flavahan N. A., Balancing prostanoid activity in the human vascular system. Trends in Pharmacological Sciences 2007 28 3 106 110 2-s2.0-33847117123 10.1016/j.tips.2007.01.003 (Pubitemid 46283588)
102. Mcadam B. F., Catella-Lawson F., Mardini I. A., Kapoor S., Lawson J. A., Fitzgerald G. A., Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proceedings of the National Academy of Sciences of the United States of America 1999 96 1 272 277 2-s2.0-0033524421 10.1073/pnas.96.1.272 (Pubitemid 29036089)
103. Rovati G. E., Sala A., Capra V., Dahlén S. E., Folco G., Dual COXIB/TP antagonists: a possible new twist in NSAID pharmacology and cardiovascular risk. Trends in Pharmacological Sciences 2010 31 3 102 107 2-s2.0-77549083579 10.1016/j.tips.2009.11.007
104. Wu K. K., Liou J. Y., Cellular and molecular biology of prostacyclin synthase. Biochemical and Biophysical Research Communications 2005 338 1 45 52 2-s2.0-27544510764 10.1016/j.bbrc.2005.08.021 (Pubitemid 41540535)
105. Liou J. Y., Shyue S. K., Tsai M. J., Chung C. L., Chu K. Y., Wu K. K., Colocalization of prostacyclin synthase with prostaglandin H synthase-1 (PGHS-1) but not phorbol ester-induced PGHS-2 in cultured endothelial cells. Journal of Biological Chemistry 2000 275 20 15314 15320 2-s2.0-0034685762 10.1074/jbc.275.20.15314 (Pubitemid 30337258)
106. Brandt R., Dembinska-Kiec A., Gryglewski R. J., Nowak J., Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation. Naunyn-Schmiedeberg's Archives of Pharmacology 1984 325 1 69 75 (Pubitemid 14157775)
107. Norel X., Haye-Legrand I., Labat C., Benveniste J., Brink C., Antigen-induced contraction of human isolated lung preparations passively sensitized with monoclonal IgE: effects of indomethacin. International Archives of Allergy and Applied Immunology 1991 96 4 368 375 2-s2.0-0026339227
108. 2 Circulation Research 1993 72 5 1023 1034 2-s2.0-0027457027 (Pubitemid 23105508)
109. Heymes C., Habib A., Yang D., Mathieu E., Marotte F., Samuel J., Boulanger C. M., Cyclo-oxygenase-1 and -2 contribution to endothelial dysfunction in ageing. British Journal of Pharmacology 2000 131 4 804 810 2-s2.0-0035224729
110. Coleman R. A., Smith W. L., Narumiya S., VIII. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacological Reviews 1994 46 2 205 229 2-s2.0-0028183018 (Pubitemid 24185151)
111. Kääpä P., Viinikka L., Ylikorkala O., Plasma prostacyclin from birth to adolescence. Archives of Disease in Childhood 1982 57 6 459 461 2-s2.0-0019980801 (Pubitemid 12070744)
112. 2 in rats and rabbits. British Journal of Pharmacology 1978 62 1 125 130 2-s2.0-0017927947 (Pubitemid 8251906)
113. Cheng Y., Wang M., Yu Y., Lawson J., Funk C. D., FitzGerald G. A., Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. Journal of Clinical Investigation 2006 116 5 1391 1399 2-s2.0-33646415952 10.1172/JCI27540
114. Fischer S., Bernutz C., Meier H., Weber P. C., Formation of prostacyclin and thromboxane in man as measured by the main urinary metabolites. Biochimica et Biophysica Acta 1986 876 2 194 199 2-s2.0-0022539007 (Pubitemid 16014851)
115. 2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation 1993 88 5 I 2117 2122 2-s2.0-0027696633 (Pubitemid 23326090)
116. Tokunaga O., Yamada T., Fan J. I., Watanabe T., Age-related decline in prostacyclin synthesis by human aortic endothelial cells: qualitative and quantitative analysis. American Journal of Pathology 1991 138 4 941 949 2-s2.0-0025855699
117. 2 in HUVEC decreased in each subsequent passage. Prostaglandins 1997 54 1 447 462 2-s2.0-0030808065 10.1016/S0090- 6980(97)00063-4 (Pubitemid 27349966)
118. Ferreira S. H., Vane J. R., Prostaglandins: their disappearance from and release into the circulation. Nature 1967 216 5118 868 873 2-s2.0-0014191125 10.1038/216868a0
119. Ishihata A., Ogaki T., Aita T., Katano Y., Role of prostaglandins in urotensin II-induced vasodilatation in the coronary arteries of aged rats. European Journal of Pharmacology 2005 523 13 119 126 2-s2.0-27644465919 10.1016/j.ejphar.2005.09.018 (Pubitemid 41562383)
120. Nicholson W. T., Vaa B., Hesse C., Eisenach J. H., Joyner M. J., Aging Is Associated with reduced prostacyclin-mediated dilation in the human forearm. Hypertension 2009 53 6 973 978 2-s2.0-67049134326 10.1161/HYPERTENSIONAHA.108. 121483
121. Hara S., Kamei D., Sasaki Y., Tanemoto A., Nakatani Y., Murakami M., Prostaglandin E synthases: understanding their pathophysiological roles through mouse genetic models. Biochimie 2010 92 6 651 659 2-s2.0-77953293751 10.1016/j.biochi.2010.02.007
122. Samuelsson B., Morgenstern R., Jakobsson P. J., Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacological Reviews 2007 59 3 207 224 2-s2.0-34748817976 10.1124/pr.59.3.1 (Pubitemid 47481434)
123. 2 Arthritis Research and Therapy 2005 7 3 114 117 2-s2.0-20144367021 10.1186/ar1748 (Pubitemid 40775173)
124. Camacho M., López-Belmonte J., Vila L., Rate of vasoconstrictor prostanoids released by endothelial cells depends on cyclooxygenase-2 expression and prostaglandin I synthase activity. Circulation Research 1998 83 4 353 365 2-s2.0-0345244848 (Pubitemid 28389965)
125. Yang T., Microsomal prostaglandin e synthase-1 and blood pressure regulation. Kidney International 2007 72 3 274 278 2-s2.0-34547472540 10.1038/sj.ki.5002326 (Pubitemid 47172379)
126. Wang M., Zukas A. M., Hui Y., Ricciotti E., Puré E., FitzGerald G. A., Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proceedings of the National Academy of Sciences of the United States of America 2006 103 39 14507 14512 2-s2.0-33749263692 10.1073/pnas.0606586103 (Pubitemid 44484780)
127. Sugimoto Y., Narumiya S., Prostaglandin E receptors. Journal of Biological Chemistry 2007 282 16 11613 11617 2-s2.0-34249729416 10.1074/jbc.R600038200 (Pubitemid 47100657)
128. Alfranca A., Iñiguez M. A., Fresno M., Redondo J. M., Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases. Cardiovascular Research 2006 70 3 446 456 2-s2.0-33747466079 10.1016/j.cardiores.2005.12.020 (Pubitemid 44255556)
129. Shio H., Shaw J., Ramwell P., Relation of cyclic AMP to the release and actions of prostaglandins. Annals of the New York Academy of Sciences 1971 185 327 335 2-s2.0-0015246474
130. Salzman E. W., Kensler P. C., Levine L., Cyclic 3',5'-adenosine monophosphate in human blood platelets. IV. Regulatory role of cyclic amp in platelet function. Annals of the New York Academy of Sciences 1972 201 61 71 2-s2.0-0015526135
131. 2 potentiation of platelet aggregation induced by LASS endoperoxide: absent in storage pool disease, normal after aspirin ingestion. British Journal of Haematology 1976 32 2 257 272 2-s2.0-0017105483
132. 2 in the blood circulation contribute to a febrile response in rabbits? Brain Research Bulletin 1992 29 2 189 192 2-s2.0-0026610780 10.1016/0361-9230(92)90025-S
133. Bergstorem S., Ryhage R., Samuelsson B., Sjoevall J., Prostaglandins and related factors. 15. The structures of prostaglandin E1, F1- α and F1- β The Journal of Biological Chemistry 1963 238 3555 3564
134. 2 Falpha, and 13, 14-dihydro-15-keto Falpha in the dog. Kidney International 1978 13 2 36 43 2-s2.0-0017928714
135. Liston T. E., Roberts L. J. II, Transformation of prostaglandin D2 to 9 α11 β -(15S)-trihydroxyprosta-(5Z,13E)-dien-1-oic acid (9 α11 β -prostaglandin F2): a unique biologically active prostaglandin produced enzymatically in vivo in humans. Proceedings of the National Academy of Sciences of the United States of America 1985 82 18 6030 6034 (Pubitemid 16223892)
136. Beasley C. R., Robinson C., Featherstone R. L., 9 α11 β -prostaglandin F2, a novel metabolite of prostaglandin D2 is a potent contractile agonist of human and guinea pig airways. Journal of Clinical Investigation 1987 79 3 978 983 (Pubitemid 17050927)
137. Helliwell R. J., Adams L. F., Mitchell M. D., Prostaglandin synthases: recent developments and a novel hypothesis. Prostaglandins Leukotrienes and Essential Fatty Acids 2004 70 2 101 113 2-s2.0-0942301255 10.1016/j.plefa.2003. 04.002 (Pubitemid 38141900)
138. Fukunaga M., Makita N., Roberts L. J. 2nd, Morrow J. D., Takahashi K., Badr K. F., Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. American Journal of Physiology 1993 264 6 C1619 C1624 2-s2.0-0027158234 (Pubitemid 23198533)
139. Abramovitz M., Boie Y., Nguyen T., Rushmore T. H., Bayne M. A., Metters K. M., Slipetz D. M., Grygorczyk R., Cloning and expression of a cDNA for the human prostanoid FP receptor. Journal of Biological Chemistry 1994 269 4 2632 2636 2-s2.0-0028101314 (Pubitemid 24235760)
140. Lake S., Gullverg H., Wahlqvist J., Cloning of the rat and human prostaglandin F2 alpha receptors and the expression of the rat prostaglandin F2 alpha receptor. FEBS Letters 1994 355 3 317 325
141. Sakamoto K., Ezashi T., Miwa K., Okuda-Ashitaka E., Houtani T., Sugimoto T., Ito S., Hayaishi O., Molecular cloning and expression of a cDNA of the bovine prostaglandin F2 alpha receptor. Advances in Prostaglandin, Thromboxane, and Leukotriene Research 1995 23 259 261 2-s2.0-0029182729
142. Sugimoto Y., Hasumoto K., Namba T., Irie A., Katsuyama M., Negishi M., Kakizuka A., Narumiya S., Ichikawa A., Cloning and expression of a cDNA for mouse prostaglandin F receptor. Journal of Biological Chemistry 1994 269 2 1356 1360 2-s2.0-0028157978 (Pubitemid 24032530)
143. Csepli J., Csapo A. I., The effect of the prostaglandin F2 α analogue ICI 81008 on uterine small arteries and on blood pressure. Prostaglandins 1975 10 4 689 697 2-s2.0-0016589949
144. Hata A. N., Breyer R. M., Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacology and Therapeutics 2004 103 2 147 166 2-s2.0-4444262310 10.1016/j.pharmthera.2004. 06.003 (Pubitemid 39209041)
145. Smyth E. M., Grosser T., Wang M., Yu Y., FitzGerald G. A., Prostanoids in health and disease. Journal of Lipid Research 2009 50 S423 428 2-s2.0-66349102248 10.1194/jlr.R800094-JLR200
146. Wong S. L., Leung F. P., Vanhoutte P., Huang Y., Endothelium-dependent contractions in hamster aorta: the essential role of COX-2 and prostaglandin-2 α Basic, Basic and Clinical Pharmacology and Toxicology 2008 102 15 15
147. Wong S. L., Leung F. P., Lau C. W., Au C. L., Yung L. M., Yao X., Chen Z. -Y., Vanhoutte P. M., Gollasch M., Huang Y., Cyclooxygenase-2-derived prostaglandin F2 α mediates endothelium-dependent contractions in the aortae of hamsters with increased impact during aging. Circulation Research 2009 104 2 228 235 10.1161/CIRCRESAHA.108.179770
148. Yu Y., Lucitt M. B., Stubbe J., Cheng Y., Friis U. G., Hansen P. B., Jensen B. L., Smyth E. M., FitzGerald G. A., Prostaglandin F2 α elevates blood pressure and promotes atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America 2009 106 19 7985 7990 2-s2.0-66049162137 10.1073/pnas.0811834106
149. Adams J. W., Migita D. S., Yu M. K., Young R., Hellickson M. S., Castro-Vargas F. E., Domingo J. D., Lee P. H., Bui J. S., Henderson S. A., Prostaglandin F2 α stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. Journal of Biological Chemistry 1996 271 2 1179 1186 2-s2.0-0029664565
150. Lai J., Jin H., Yang R., Winer J., Wei L. I., Yen R., King K. L., Zeigler F., Annie K. O., Cheng J., Bunting S., Paoni N. F., Prostaglandin F2 α induces cardiac myocyte hypertrophy in vitro and cardiac growth in vivo. American Journal of Physiology 1996 271 6 H2197 H2208 2-s2.0-0030338193
151. Pönicke K., Giessler C., Grapow M., Heinroth-Hoffmann I., Becker K., Osten B., Brodde O. E., FP-receptor mediated trophic effects of prostanoids in rat ventricular cardiomyocytes. British Journal of Pharmacology 2000 129 8 1723 1731 2-s2.0-0033994984 (Pubitemid 30219016)
152. Taba Y., Sasaguri T., Miyagi M., Abumiya T., Miwa Y., Ikeda T., Mitsumata M., Fluid shear stress induces lipocalin-type prostaglandin D2 synthase expression in vascular endothelial cells. Circulation Research 2000 86 9 967 973 2-s2.0-0034640235 (Pubitemid 30324309)
153. Jones R. L., Giembycz M. A., Woodward D. F., Prostanoid receptor antagonists: development strategies and therapeutic applications. British Journal of Pharmacology 2009 158 1 104 145 2-s2.0-69249211014 10.1111/j.1476-5381.2009.00317.x
154. VanderEnde D. S., Morrow J. D., Release of markedly increased quantities of prostaglandin D2 from the skin in vivo in humans after the application of cinnamic aldehyde. Journal of the American Academy of Dermatology 2001 45 1 62 67 2-s2.0-0034939251 10.1067/mjd.2001.113694 (Pubitemid 32655694)
155. Walch L., Labat C., Gascard J. P., de Montpreville V., Brink C., Norel X., Prostanoid receptors involved in the relaxation of human pulmonary vessels. British Journal of Pharmacology 1999 126 4 859 866 2-s2.0-0032934180 (Pubitemid 29103701)
156. 2 in the dog. Prostaglandins 1977 13 2 255 269 (Pubitemid 8049082)
157. Hardy C. C., Robinson C., Tattersfield A. E., Holgate S. T., The bronchoconstrictor effect of inhaled prostaglandin D2 in normal and asthmatic men. New England Journal of Medicine 1984 311 4 209 213 2-s2.0-0021141316 (Pubitemid 14087661)
158. Johnston S. L., Freezer N. J., Ritter W., O'Toole S., Howarth P. H., Prostaglandin D2-induced bronchoconstriction is mediated only in part by the thromboxane prostanoid receptor. European Respiratory Journal 1995 8 3 411 415 2-s2.0-0028986360
159. 2 on platelet aggregation in different species. Prostaglandins 1978 16 3 373 388 2-s2.0-0018076975 (Pubitemid 9032516)
160. Cooper B., Diminished platelet adenylate cyclase activation by prostaglandin D2 in acute thrombosis. Blood 1979 54 3 684 693 2-s2.0-0018693037 (Pubitemid 10227867)
161. Siegl A. M., Receptors for PGI2 and PGD2 on human platelets. Methods in Enzymology 1982 86 179 192 2-s2.0-0020009424 10.1016/0076-6879(82)86189-2
162. Thierauch K. H., Stürzebecher C. S., Schillinger E., Rehwinkel H., Radüchel B., Skuballa W., Vorbrüggen H., Stable 9 beta- or 11 alpha-halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD2-receptor. Advances in Prostaglandin, Thromboxane, and Leukotriene Research 1989 19 655 658 2-s2.0-0024540540
163. Kiriyama M., Ushikubi F., Kobayashi T., Hirata M., Sugimoto Y., Narumiya S., Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. British Journal of Pharmacology 1997 122 2 217 224 2-s2.0-0030871070 10.1038/sj.bjp.0701367 (Pubitemid 27397191)
164. 2 Science 2002 296 5567 539 541 2-s2.0-0037134011 10.1126/science.1068711 (Pubitemid 34408674)
165. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. Journal of Clinical Investigation 2004 114 6 784 794 2-s2.0-9644272529 10.1172/JCI200421446 (Pubitemid 39578737)
166. Francois H., Athirakul K., Mao L., Rockman H., Coffman T. M., Role for thromboxane receptors in angiotensin-II-induced hypertension. Hypertension 2004 43 2 364 369 2-s2.0-0842311498 10.1161/01.HYP.0000112225.27560.24 (Pubitemid 38174140)
167. 2 in blood vessel walls and its physiological significance: relevance to thrombosis and hypertension. Prostaglandins and Medicine 1980 4 6 431 438 2-s2.0-0018854149 (Pubitemid 10110057)
168. 2 receptors. American Journal of Physiology 1991 260 2 H327 H334 2-s2.0-0026061235
169. Spurney R. F., Bernstein R. J., Ruiz P., Pisetsky D. S., Coffman T. M., Physiologic role for enhanced renal thromboxane production in murine lupus nephritis. Prostaglandins 1991 42 1 15 28 2-s2.0-0025759111 10.1016/0090- 6980(91)90090-3
170. Katugampola S. D., Davenport A. P., Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT1 receptor antagonist losartan. British Journal of Pharmacology 2001 134 7 1385 1392 2-s2.0-0035214283 (Pubitemid 33131888)
171. Martin W., The combined role of atheroma, cholesterol, platelets, the endothelium and fibrin in heart attacks and strokes. Medical Hypotheses 1984 15 3 305 322 2-s2.0-0021703286 (Pubitemid 15199005)
172. 2 receptors in patients with acute myocardial infarction. Circulation 1990 81 1 212 218 2-s2.0-0025177234 (Pubitemid 20031785)
173. Dogne J. M., Hanson J., Pratico D., Thromboxane, prostacyclin andisoprostanes: therapeutic targets in atherogenesis. Trends in Pharmacological Sciences 2005 26 12 639 644 (Pubitemid 41636309)
174. Lüscher T. F., Boulanger C. M., Dohi Y., Yang Z. H., Endothelium-derived contracting factors. Hypertension 1992 19 2 117 130 2-s2.0-0026532764
175. Félétou M., Vanhoutte P. M., Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). American Journal of Physiology 2006 291 3 H985 H1002 (Pubitemid 44343640)
176. Fitzgerald D. J., Roy L., Catella F., Fitzderald G. A., Platelet activation in unstable coronary disease. New England Journal of Medicine 1986 315 16 983 989 (Pubitemid 16028578)
177. + channels via the EP3 receptor. American Journal of Physiology 2005 288 5 H2093 H2101 2-s2.0-18044393459 10.1152/ajpheart.01003.2004 (Pubitemid 40604092)
178. 2 synthesis in pregnancy-induced hypertension. Lancet 1990 335 8692 751 754 2-s2.0-0025195422 10.1016/0140-6736(90)90869-7 (Pubitemid 20106682)
179. Keith J. C. Jr., Spitz B., van Assche F. A., Thromboxane synthetase inhibition as a new therapy for preeclampsia: animal and human studies minireview. Prostaglandins 1993 45 1 3 13 2-s2.0-0027400387 10.1016/0090- 6980(93)90085-L (Pubitemid 23043103)
180. 2 on thoracic aorta of young and old rats: use of selective thromboxane receptor antagonists. Pharmacology 1990 40 1 27 32 2-s2.0-0025194399 (Pubitemid 20081586)
181. Vanhoutte P. M., Tang E. H., Endothelium-dependent contractions: when a good guy turns bad! Journal of Physiology 2008 586 22 5295 5304 2-s2.0-56649094583 10.1113/jphysiol.2008.161430
182. Hornych A., Forette F., Bariety J., Krief C., Aumont J., Paris M., The influence of age on renal prostaglandin synthesis in man. Prostaglandins Leukotrienes and Essential Fatty Acids 1991 43 3 191 195 2-s2.0-0025789152 10.1016/0952-3278(91)90168-5
183. Hou J., Abe K., Yoshinaga K., The investigation about age-related changes in vasoactive substances of normal subjects and of patients with essential hypertension. Nippon Jinzo Gakkai Shi 1992 34 3 287 293
184. Lüscher T. F., Imbalance of endothelium-derived relaxing and contracting factors: a new concept in hypertension? American Journal of Hypertension 1990 3 4 317 330 2-s2.0-0025289182 (Pubitemid 20215206)
185. Christman B. W., McPherson C. D., Newman J. H., King G. A., Bernard G. R., Groves B. M., Loyd J. E., An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. New England Journal of Medicine 1992 327 2 70 75 2-s2.0-0026628265
186. Woodman C. R., Price E. M., Laughlin M. H., Selected Contribution: aging impairs nitric oxide and prostacyclin mediation of endothelium-dependent dilation in soleus feed arteries. Journal of Applied Physiology 2003 95 5 2164 2170 2-s2.0-0142242298 (Pubitemid 37310405)
187. Zou M. H., Ullrich V., Peroxynitrite formed by simultaneous generation of nitric oxide and superoxide selectively inhibits bovine aortic prostacyclin synthase. FEBS Letters 1996 382 1-2 101 104 2-s2.0-0029879266 10.1016/0014-5793(96)00160-3 (Pubitemid 26092944)
188. Santilli F., Davì G., Basili S., Lattanzio S., Cavoni A., Guizzardi G., De feudis L., Traisci G., Pettinella C., Paloscia L., Minuz P., Meneguzzi A., Ciabattoni G., Patrono C., Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. Journal of Thrombosis and Haemostasis 2010 8 5 914 922 2-s2.0-77953750362 10.1111/j.1538-7836.2010.03820.x
189. Sellers M. M., Stallone J. N., Sympathy for the devil: the role of thromboxane in the regulation of vascular tone and blood pressure. American Journal of Physiology 2008 294 5 H1978 H1986 2-s2.0-44949101426 10.1152/ajpheart.01318.2007
190. Félétou M., Vanhoutte P. M., Verbeuren T. J., The thromboxane/endoperoxide receptor (TP): the common villain. Journal of Cardiovascular Pharmacology 2010 55 4 317 332 2-s2.0-77951712638 10.1097/FJC.0b013e3181d8bc8a
191. 2 in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 2001 104 18 2210 2215 2-s2.0-0035975983 (Pubitemid 33043302)
192. 2 Science 2002 296 5567 539 541 2-s2.0-0037134011 10.1126/science.1068711 (Pubitemid 34408674)
193. Arehart E., Stitham J., Asselbergs F. W., Douville K., MacKenzie T., Fetalvero K. M., Gleim S., Kasza Z., Rao Y., Martel L., Segel S., Robb J., Kaplan A., Simons M., Powell R. J., Moore J. H., Rimm E. B., Martin K. A., Hwa J., Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circulation Research 2008 102 8 986 993 2-s2.0-42549150113 10.1161/CIRCRESAHA. 107.165936 (Pubitemid 351591551)
194. Ross R., The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993 362 6423 801 809 2-s2.0-0027241856 10.1038/362801a0 (Pubitemid 23132154)
195. Baker C. S., Hall R. J. C., Evans T. J., Pomerance A., Maclouf J., Creminon C., Yacoub M. H., Polak J. M., Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplanted human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology 1999 19 3 646 655 2-s2.0-0033015661 (Pubitemid 29135167)
196. Hong B. K., Kwon H. M., Lee B. K., Kim D., Kim I. J., Kang S. M., Jang Y., Cho S. H., Kim H. K., Jang B. C., Cho S. Y., Kim H. S., Kim M. S., Kwon H. C., Lee N., Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Medical Journal 2000 41 1 82 88 2-s2.0-17144454444
197. Schonbeck U., Sukhova G. K., Graber P., Coulter S., Libby P., Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. American Journal of Pathology 1999 155 4 1281 1291 2-s2.0-0032833967 (Pubitemid 29488935)
198. Stemme V., Swedenborg J., Claesson H. E., Hansson G. K., Expression of cyclo-oxygenase-2 in human atherosclerotic carotid arteries. European Journal of Vascular and Endovascular Surgery 2000 20 2 146 152 2-s2.0-0033841366 10.1053/ejvs.2000.1145 (Pubitemid 30649641)
199. Chen Y. F., Jowett S., Barton P., Malottki K., Hyde C., Gibbs J. S., Pepke-Zaba J., Fry-Smith A., Roberts J., Moore D., Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technology Assessment 2009 13 49 1 320 2-s2.0-75649116508
200. Peter C. S., Peter C., Prostaglandins, prostacyclin, and thromboxane in cardiovascular diseases. Drug Development Research 1986 7 4 341 359 2-s2.0-0022469664
201. McLaughlin V. V., Gaine S. P., Barst R. J., Oudiz R. J., Bourge R. C., Frost A., Robbins I. M., Tapson V. F., McGoon M. D., Badesch D. B., Sigman J., Roscigno R., Blackburn S. D., Arneson C., Rubin L. J., Rich S., Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. Journal of Cardiovascular Pharmacology 2003 41 2 293 299 2-s2.0-12244251412 10.1097/00005344-200302000-00019 (Pubitemid 36135255)
202. Toda N., Beraprost sodium. Cardiovascular Drug Reviews 1988 6 3 222 238 2-s2.0-0024160132 (Pubitemid 19242135)
203. 2 analogue. Japanese Journal of Pharmacology 1987 43 1 81 90 (Pubitemid 17207613)
204. Umetsu T., Murata T., Nishio S., Studies on the antiplatelet effect of the stable epoprostenol analogue beraprost sodium and its mechanism of action in rats. Arzneimittel-Forschung 1989 39 1 68 73 2-s2.0-0024532937 (Pubitemid 19030789)
205. Murai T., Muraoka K., Saga K., Sakai A., Sato N., Amemiya K., Yajima M., Murata T., Umetsu T., Nishio S., Effect of beraprost sodium on peripheral circulation insufficiency in rats and rabbits. Arzneimittel-Forschung 1989 39 8 856 859 2-s2.0-0024405061 (Pubitemid 19204687)
206. Ma X. L., Johnson G. 3rd, Lefer A. M., Low doses of superoxide dismutase and a stable prostacyclin analogue protect in myocardial ischemia and reperfusion. Journal of the American College of Cardiology 1992 19 1 197 204 2-s2.0-0026595534
207. 2 methyl ester]: (I) Vasodilation. Journal of Hypertension 1986 4 6 741 747 (Pubitemid 17217656)
208. 2 methyl ester]: (II) Effects on the adrenergic nervous system. Journal of Hypertension 1986 4 6 749 757 (Pubitemid 17217657)
209. 2 on renin release in patients with congestive heart failure. Circulation 1986 74 6 1203 1207 2-s2.0-0022978641 (Pubitemid 17189238)
210. Haas J. A., Hammond T. G., Granger J. P., Blaine E. H., Knox F. G., Mechanism of natriuresis during intrarenal infusion of prostaglandins. The American Journal of Physiology 1984 247 3 F475 479 2-s2.0-18544394083 (Pubitemid 14046249)
211. 2 The American Journal of Physiology 1984 247 4 F555 561 2-s2.0-0021504894 (Pubitemid 15209761)
212. Stokes J. B., Integrated actions of renal medullary prostaglandins in the control of water excretion. The American Journal of Physiology 1981 240 6 F471 F480 2-s2.0-0019581538 (Pubitemid 11073332)
213. Olley P. M., Coceani F., Bodach E., E-type prostaglandins: a new emergency therapy for certain cyanotic congenital heart malformations. Circulation 1976 53 4 728 731 2-s2.0-0017133691
214. Heymann M. A., Pharmacologic use of prostaglandin E1 in infants with congenital heart disease. American Heart Journal 1981 101 6 837 843 2-s2.0-0019732881 (Pubitemid 11126239)
215. 2 in management of ductus dependent congenital heart disease. Archives of Disease in Childhood 1985 60 11 1025 1030 2-s2.0-0022343487 (Pubitemid 16194236)
216. 2 in ductus-dependent pulmonary circulation. Circulation 1981 63 3 682 688 (Pubitemid 11139881)
217. Fiddler G. I., Lumley P., Preliminary clinical studies with thromboxane synthase inhibitors and thromboxane receptor blockers. A review. Circulation 1990 81 1 supplement I I -69 I -78
218. Jones E. W., Cockbill S. R., Cowley A. J., Effects of dazoxiben and low-dose aspirin on platelet behaviour in man. British Journal of Clinical Pharmacology 1983 15 supplement 1 39S 44S (Pubitemid 13093791)
219. Villalobos M. A., de La Cruz J. P., Escalante R., Arrebola M. M., Guerrero A., Sánchez de la Cuesta F., Effects of camonagrel, a selective inhibitor of platelet thromboxane synthase, on the platelet-subendothelium interaction. Pharmacology 2003 69 1 44 50 2-s2.0-0043175383 10.1159/000071266 (Pubitemid 36928723)
220. Coker S. J., Parratt J. R., The effects of dazoxihen on arrhythmias and ventricular fibrillation induced by coronary, artery occlusion and reperfusion. British Journal of Clinical Pharmacology 1983 15 supplement 1 87S 95S (Pubitemid 13093801)
221. Coker S. J., Further evidence that thromboxane exacerbates arrhythmias: effects of UK38485 during coronary artery occlusion and reperfusion in anaesthetized greyhounds. Journal of Molecular and Cellular Cardiology 1984 16 7 633 641 2-s2.0-0021624572 (Pubitemid 15044102)
222. 2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. European Heart Journal 2004 25 20 1845 1852 2-s2.0-4944241267 10.1016/j.ehj.2004.07.013 (Pubitemid 39330236)
223. Vetrano A., Milani M., Corsini G., Effects of aspirin or picotamide, an antithromboxane agent, in combination with low-intensity oral anticoagulation in patients with acute myocardial infarction: a controlled randomized pilot trial. Giornale Italiano di Cardiologia Journal 1999 29 5 524 528 2-s2.0-0032941161 (Pubitemid 29230170)
224. Cocozza M., Picano T., Oliviero U., Russo N., Coto V., Milani M., Effects of picotamide, an antithromboxane agent, on carotid atherosclerotic evolution: a two-year, double-blind, placebo-controlled study in diabetic patients. Stroke 1995 26 4 597 601 2-s2.0-0028964860
225. Hennerici M. G., Bots M. L., Ford I., Laurent S., Touboul P. J., Rationale, design and population baseline characteristics of the PERFORM Vascular Project: an ancillary study of the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial. Cardiovascular Drugs and Therapy 2010 24 2 175 180 2-s2.0-77955424662 10.1007/s10557-010-6231-2
226. Simonet S., Descombes J. J., Vallez M. O., S 18886, a new thromboxane (TP)-receptor antagonist is the active isomer of S 18204 in all species, except in the guinea-pig. Advances in Experimental Medicine and Biology 1997 433 173 176 (Pubitemid 28231807)
227. Johnson A. G., Nguyen T. V., Day R. O., Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Annals of Internal Medicine 1994 121 4 289 300 2-s2.0-0028580588
228. Swan S. K., Rudy D. W., Lasseter K. C., Ryan C. F., Buechel K. L., Lambrecht L. J., Pinto M. B., Dilzer S. C., Obrda O., Sundblad K. J., Gumbs C. P., Ebel D. L., Quan H., Larson P. J., Schwartz J. I., Musliner T. A., Gertz B. J., Brater D. C., Yao S. L., Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Annals of Internal Medicine 2000 133 1 1 9 2-s2.0-0034604272 (Pubitemid 30432538)
229. Hawkey C. J., Hawkey G. M., Everitt S., Skelly M. M., Stack W. A., Gray D., Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology 2006 61 6 730 737 2-s2.0-33646905898 10.1111/j.1365-2125.2006.02644.x (Pubitemid 43794802)
230. Husain S., Andrews N. P., Mulcahy D., Panza J. A., Quyyumi A. A., Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998 97 8 716 720 2-s2.0-0032478097 (Pubitemid 28135332)
231. Fuster V., Dyken M. L., Vokonas P. S., Hennekens C., Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group. Circulation 1993 87 2 659 675 (Pubitemid 23040943)
232. Antiplatelet Trials Collaboration, Collaborative overview of randomized trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. British Medical Journal 1994 308 6921 81 106 2-s2.0-0028120906
233. Roth G. J., Majerus P. W., The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein, Annual Review of Pharmacology and Toxicology. The Journal of Clinical Investigation 1975 56 3 624 632
234. 2 synthase. Nature Structural & Molecular Biology 1995 2 8 637 643 2-s2.0-0029056992
235. Vane J. R., Bakhle Y. S., Botting R. M., Cyclooxygenases 1 and 2. Annual Review of Pharmacology and Toxicology 1998 38 97 120 2-s2.0-0031777185 (Pubitemid 28231490)
236. Pignatelli P., di Santo S., Barillá F., Gaudio C., Violi F., Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance. Journal of Thrombosis and Haemostasis 2008 6 10 1832 1834 2-s2.0-52649141014 10.1111/j.1538-7836.2008.03122.x
237. Dawson J., Quinn T., Rafferty M., Higgins P., Ray G., Lees K. R., Walters M. R., Aspirin resistance and compliance with therapy. Cardiovascular Therapeutics 2011 29 5 301 307 10.1111/j.1755-5922.2010.00188.x
238. Di Minno G., Aspirin resistance and platelet turnover: a 25-year old issue. Nutrition, Metabolism and Cardiovascular Diseases 2011 21 8 542 545 10.1016/j.numecd.2011.04.002
239. Szczeklik A., Musia J., Undas A., Sanak M., Aspirin resistance. Journal of Thrombosis and Haemostasis 2005 3 8 1655 1662 2-s2.0-28344454159 10.1111/j.1538-7836.2005.01372.x (Pubitemid 41716551)
240. Goodman T., Ferro A., Sharma P., Pharmacogenetics of aspirin resistance: a comprehensive systematic review. British Journal of Clinical Pharmacology 2008 66 2 222 331 2-s2.0-47249143688 10.1111/j.1365-2125.2008.03183.x (Pubitemid 351991440)
241. Krasopoulos G., Brister S. J., Beattie W. S., Buchanan M. R., Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. British Medical Journal 2008 336 7637 195 198 10.1136/bmj.39430.529549.BE (Pubitemid 351212675)
242. Snoep J. D., Hovens M. M., Eikenboom J. C., van der Bom J. G., Huisman M. V., Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Archives of Internal Medicine 2007 167 15 1593 1599 2-s2.0-34447503098 10.1001/archinte.167.15.1593 (Pubitemid 47280339)
243. Eikelboom J. W., Hirsh J., Weitz J. I., Johnston M., Yi Q., Yusuf S., Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002 105 14 1650 1655 2-s2.0-0037046196 10.1161/01.CIR.0000013777.21160.07 (Pubitemid 34298607)
244. +-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological function. Current Pharmaceutical Design 2006 12 8 955 962 2-s2.0-33645979989 10.2174/138161206776055958
245. Rudock M. E., Liu Y., Ziegler J. T., Allen S. G., Lehtinen A. B., Freedman B. I., Carr J. J., Langefeld C. D., Bowden D. W., Association of polymorphisms in cyclooxygenase (COX)-2 with coronary and carotid calcium in the Diabetes Heart Study. Atherosclerosis 2009 203 2 459 465 2-s2.0-62649173099 10.1016/j.atherosclerosis.2008.07.018
246. Helmersson J., Ärnlöv J., Axelsson T., Basu S., A polymorphism in the cyclooxygenase 1 gene is associated with decreased inflammatory prostaglandin F2 α formation and lower risk of cardiovascular disease. Prostaglandins Leukotrienes and Essential Fatty Acids 2009 80 1 51 56 2-s2.0-59649114900 10.1016/j.plefa.2008.11.001
247. Nakayama T., Prostacyclin synthase gene: genetic polymorphisms and prevention of some cardiovascular diseases. Current Medicinal Chemistry: Cardiovascular and Hematological Agents 2005 3 2 157 164 2-s2.0-17144372899 10.2174/1568016053544327 (Pubitemid 40514790)
248. Stitham J., Stojanovic A., Hwa J., Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. Journal of Biological Chemistry 2002 277 18 15439 15444 2-s2.0-0037013211 10.1074/jbc.M201187200 (Pubitemid 34967808)
249. Lemaitre R. N., Rice K., Marciante K., Bis J. C., Lumley T. S., Wiggins K. L., Smith N. L., Heckbert S. R., Psaty B. M., Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. Atherosclerosis 2009 204 2 e58 e63 2-s2.0-67349271287 10.1016/j.atherosclerosis.2008.10.011
250. Hamberg M., Samuelsson B., On the metabolism of prostaglandins E 1 and E 2 in man. Journal of Biological Chemistry 1971 246 22 6713 6721 2-s2.0-0015240355
251. Nomura R., Lu R., Pucci M. L., Schuster V. L., The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Molecular Pharmacology 2004 65 4 973 978 2-s2.0-1842532964 10.1124/mol.65.4.973 (Pubitemid 38420503)
252. Chang H. Y., Locker J., Lu R., Schuster V. L., Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice. Circulation 2010 121 4 529 536 2-s2.0-76349088956 10.1161/CIRCULATIONAHA.109. 862946
253. Chi Y. Min J. Jasmin J.F. Lisanti M.P. Chang Y.T. Schuster V.L. Development of a high affinity inhibitor of the prostaglandin transporter PGT Journal of Pharmacology and Experimental Therapeutics 2011 339 2 529-536 10.1124/jpet.111.181354